
20 Years of IBEC
Shaping the present and future of medicine with Bioengineering

Global health cannot advance without science, engineering, and innovation technologies.
We shape the present and future of medicine with Bioengineering.
From excellent research to innovative solutions, IBEC merges science and engineering for Active Ageing, Future Medicine and Regenerative Therapies

CERCA Center

Member of

Recognised by:


Latest News
IBEC in the media
MEDICAL DAILY: Light-Activated Compounds Designed to Stand In for Lost Photoreceptors Restore Visual Behavior in Blind Animals
A research consortium led by the Institute for Bioengineering of Catalonia in Barcelona has developed a family of light-switchable small molecules designed to occupy the gap. The compounds, called prosthe6, restored visual responses in zebrafish and mouse models of retinal degeneration under ordinary ambient light.
EL ECONOMISTA: Lumiris fabrica las primeras unidades de su plataforma para revolucionar la reproducción asistida
La biotecnológica española Lumiris avanza en su nueva ronda de financiación tras captar ocho millones.
REVISTA CAPITAL: El talento que impulsa la investigación del futuro
Las becas de la Fundación ‘la Caixa’ espolean las carreras investigadoras en el ámbito de la salud. Irene Marco: “Sin esta beca, seguramente no habría vuelto a España”.
PHYS.ORG: Prolonged stretching reorganizes tissue scaffolds and uncages cell nuclei
How do tissues cope with being stretched for hours or even days? A study led by researchers at the Institute for Bioengineering of Catalonia (IBEC) has uncovered an unexpected answer: Cells radically reorganize their internal scaffolding and, in the process, release their nuclei from a protective keratin network.
A MEDIA SESIÓN | RADIO INTERECONOMÍA: Ratones ciegos que recuperan la vista con un fármaco
Entrevista a la investigadora Rosalba Sortino, sobre los fármacos activados por luz que restauran la visión en ratones ciegos.
3Cat | TELENOTÍCIES MIGDIA: Ratolins cecs recuperen la visió amb un nou fàrmac
El Instituto de Biotecnología de Cataluña lidera una investigación que ha desarrollado un fármaco en forma de colirio que permite recuperar la visión en ratones ciegos, con ensayos clínicos previstos en humanos en cuatro años. Declaraciones de Rosalba Sortino, autora del estudio Instituto de bioingeniería de Cataluña.; Joaquín Martínez Tambella, coautor del estudio Instituto de Biotecnología de Cataluña.
AGENZIA ANSA: Ripristinata la vista nei topi con un farmaco attivato dalla luce
Un farmaco attivato dalla luce ha ripristinato la vista nei topi: funziona come una sorta di ‘protesi molecolare’ che sostituisce i sensori della retina ormai degenerati a causa della malattia, riattivando il circuito che trasporta i segnali al cervello.
EL MUNDO: “Prótesis molecular” para la retina dañada: crean fármacos activados por luz que restauran la visión en ratones ciegos
Un consorcio internacional liderado por el IBEC ha desarrollado unos compuestos inteligentes que imitan las células fotorreceptoras dañadas en algunas enfermedades degenerativas. El avance abre la puerta a futuros tratamientos no invasivos mediante colirios.


Cookies are important to you: they influence your browsing experience, help us protect your privacy, and allow us to process the requests you make through the website. We use our own and third-party cookies to analyze our services and show you advertising related to your preferences, based on a profile created from your browsing habits. You can “Accept” or “Reject” non-essential cookies, as well as configure your preferences by clicking “Configure Cookies.” For more information, please consult our Cookie Policy.


